Entyvio Outperforms Anti-TNF Alpha Therapies in Real-world Bowel Disease Studies

Entyvio Outperforms Anti-TNF Alpha Therapies in Real-world Bowel Disease Studies
Real-world treatment results showed that  Takeda's Entyvio (vedolizumab) was better than an anti-tumor necrosis factor-alpha therapy at alleviating moderate to severe ulcerative colitis or Crohn's disease, according to several studies. They showed that Entyvio, a biologic, did a better job than anti-TNF-alpha therapy at  healing the mucus that lines intestines and of achieving endoscopic remission — an end to inflammation that a doctor can spot with a scope. Researchers presented the studies at the 13th Congress of the European Crohn's and Colitis Organization in Vienna, Feb. 14-17. In one study, the U.S. Victory consortium compared Entyvio and anti-TNF-alpha's ability to treat 334 ulcerative colitis and 538 Crohn's patients. The consortium, whose name stands for Vedolizumab for Health OuTComes in InflammatORY Bowel Diseases, is a partnership of 10 leading U.S. inflammatory bowel disease centers. Half the patients in each disease group received Entyvio and the other half anti-TNF-alpha treatment. Men accounted for 49% of ulcerative colitis patients and 44% of Crohn's patients. Patients' mean age was 35 years. Researchers matched the disease characteristics of the two groups before treatment started. The team used three effectiveness measures. One was mucus healing. The yardstick for ulcerative colitis patients was a Mayo endoscopic score of 0 or 1. The yardstick for Crohn's patients was no ulcers or intestinal tissue damage. A second effectiveness measure was disease remission, with the yardstick being no symptoms according to the Physician Global Assessment scale. The third effectiveness measure was achieving remission without steroids. A key fi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *